Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences HOPKINTON, Mass. and SANTA CLARA, Calif., April 25 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (NASDAQ:CALP) and Affymetrix, Inc. (NASDAQ: AFFX) today announced that Caliper has issued Affymetrix a non-exclusive license to use a portion of Caliper's microfluidics patent estate with Affymetrix' GeneChip(R) microarray technologies. The license extends to the manufacture and sale of GeneChip brand products in all areas of application, including research, diagnostics and applied genomics applications. In exchange for the license, Affymetrix will pay upfront licensing fees and royalties on future products covered under the agreement. Further financial details related to the agreement were not disclosed. The agreement announced today is the second agreement since Caliper began an active program to out-license its intellectual property portfolio. The new "LabChip Driven" program was put in place to support the company's microfluidics adoption strategy and to broaden and accelerate the availability of new technologies and products for life science and diagnostics applications. "The potential for merging two technologies on the forefront of life science innovation represents an important option for us," said Alan Sherr, Director of Licensing for Affymetrix. "We have worked successfully with Caliper as a partner for a year now, and are pleased to be able to extend the scope of our relationship with Caliper to this new area of potential value and importance to Affymetrix' customers." "We are pleased that a leading life sciences company like Affymetrix recognizes the vast potential of LabChip technologies," said Kevin Hrusovsky, President and CEO at Caliper. "Affymetrix is moving beyond basic research applications and is pioneering areas such as pharmacogenomics and personalized medicine. Incorporating our technologies -- first laboratory automation and now the potential for Caliper's microfluidics technologies -- into these vital areas of human health is important to our corporate ideals and to our future as a key technology provider to the industry." The scope of the license agreement includes nucleic acids processing and handling associated with GeneChip arrays, but excludes the right to use LabChip technology with respect to products intended primarily to perform nucleic acid separations as a discrete, non-integrated quality control step. About Caliper Life Sciences: Caliper Life Sciences uses its advanced liquid handling and LabChip(R) technologies to create leading edge tools that accelerate drug discovery, enable diagnosis of disease and facilitate scientific research. Caliper headquarters are located in Hopkinton, Massachusetts, with R&D, operations and manufacturing facilities for LabChip devices in Mountain View, California, and direct sales, service and applications support throughout the world. Caliper customers and partners include many of the largest pharmaceutical, biotechnology, and life sciences companies. For more information, please visit Caliper's web site at http://www.caliperls.com/. The statements in this press release regarding royalties received by Caliper for future Affymetrix product sales, Caliper's ability to out-license its intellectual property, and Caliper's ability to broaden and accelerate the availability of new technologies are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Caliper from those projected. These risk factors are discussed under the caption "Factors Affecting Operating Results" in Caliper's Form 10-K for the year ended December 31, 2004, filed with the Securities and Exchange Commission on March 16, 2005. Caliper expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Caliper's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. About Affymetrix: Affymetrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,200 systems have been shipped around the world and nearly 3,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 900 employees worldwide. All statements in this press release that are not historical are "forward- looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses, uncertainties relating to technological approaches, manufacturing, product development, market acceptance (including uncertainties relating to the benefits of the licensing agreement discussed in this press release), personnel retention, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2004 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix, Inc. LabChip and Caliper are registered trademarks of Caliper Life Sciences, Inc. DATASOURCE: Affymetrix, Inc. CONTACT: media, Wes Conard, Director, Public Relations, +1-408-731-5791, or investors, Doug Farrell, Vice President, Investor Relations, +1-408-731-5285, both of Affymetrix, Inc.; or Michele Boudreau, Director, Corporate Communications of Caliper Life Sciences, Inc., +1-650-623-0305 Web site: http://www.affymetrix.com/ http://www.caliperls.com/

Copyright